(Q42971014)

English

Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.

scientific article published on November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

phase I clinical trial

0 references

phase II clinical trial

0 references

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Pierre Chan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Roberta Pang

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Kelvin Ng

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

S T Fan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Ronnie T Poon

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

116

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

5022-5029

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20629034%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

21 January 2018

Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

21 January 2018

Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

21 January 2018

Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

21 January 2018

Estimating the world cancer burden: Globocan 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of systemic therapy of advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of advanced hepatocellular carcinoma in the era of targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25372

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42971014&oldid=1749498016"